ME03084B - Inhibiтori inhibiтora proteina apoptoze - Google Patents

Inhibiтori inhibiтora proteina apoptoze

Info

Publication number
ME03084B
ME03084B MEP-2018-161A MEP2018161A ME03084B ME 03084 B ME03084 B ME 03084B ME P2018161 A MEP2018161 A ME P2018161A ME 03084 B ME03084 B ME 03084B
Authority
ME
Montenegro
Prior art keywords
iap inhibitors
iap
inhibitors
Prior art date
Application number
MEP-2018-161A
Other languages
German (de)
English (en)
French (fr)
Inventor
Frederick Cohen
John A Flygare
Lewis J Gazzard
Vickie Hsiao-Wei Tsui
Original Assignee
Curis Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc, Genentech Inc filed Critical Curis Inc
Publication of ME03084B publication Critical patent/ME03084B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MEP-2018-161A 2012-01-03 2013-01-03 Inhibiтori inhibiтora proteina apoptoze ME03084B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261582760P 2012-01-03 2012-01-03
EP16189661.8A EP3133073B1 (en) 2012-01-03 2013-01-03 Inhibitors of iap

Publications (1)

Publication Number Publication Date
ME03084B true ME03084B (me) 2019-01-20

Family

ID=48695302

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2016-235A ME02526B (me) 2012-01-03 2013-01-03 Inhibitori iap
MEP-2018-161A ME03084B (me) 2012-01-03 2013-01-03 Inhibiтori inhibiтora proteina apoptoze

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2016-235A ME02526B (me) 2012-01-03 2013-01-03 Inhibitori iap

Country Status (41)

Country Link
US (6) US8716236B2 (me)
EP (2) EP3133073B1 (me)
JP (2) JP5747137B2 (me)
KR (3) KR101553792B1 (me)
CN (2) CN104159897A (me)
AR (2) AR089623A1 (me)
AU (1) AU2013202780B2 (me)
BR (1) BR112014016637B1 (me)
CA (1) CA2861637C (me)
CL (1) CL2014001770A1 (me)
CO (1) CO7020915A2 (me)
CR (1) CR20140367A (me)
CY (2) CY1118371T1 (me)
DK (2) DK3133073T3 (me)
EC (1) ECSP14011792A (me)
ES (2) ES2594856T3 (me)
HK (1) HK1203949A1 (me)
HR (2) HRP20161381T1 (me)
HU (2) HUE037760T2 (me)
IL (2) IL242314A (me)
LT (2) LT2800749T (me)
MA (1) MA35895B1 (me)
ME (2) ME02526B (me)
MX (1) MX336294B (me)
MY (1) MY178390A (me)
NO (1) NO2755614T3 (me)
NZ (1) NZ627480A (me)
PE (1) PE20142182A1 (me)
PH (2) PH12014501534B1 (me)
PL (2) PL2800749T3 (me)
PT (2) PT3133073T (me)
RS (2) RS55327B1 (me)
RU (2) RU2728789C2 (me)
SG (1) SG11201403784QA (me)
SI (2) SI2800749T1 (me)
SM (2) SMT201800352T1 (me)
TR (1) TR201808088T4 (me)
TW (1) TWI503318B (me)
UA (1) UA114417C2 (me)
WO (1) WO2013103703A1 (me)
ZA (1) ZA201405535B (me)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2755614T3 (me) 2012-01-03 2018-03-31
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用
IL274598B2 (en) 2017-11-13 2025-01-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd SMAC mimetics used as IAP inhibitors and their use
CN112533898A (zh) 2018-07-31 2021-03-19 日商泛美克斯股份有限公司 杂环化合物
US20220402935A1 (en) 2019-07-31 2022-12-22 Fimecs, Inc. Heterocyclic compound
US20230029259A1 (en) * 2019-12-02 2023-01-26 Ascentage Pharma (Suzhou) Co., Ltd. Combination of iap inhibitors and parp or mek inhibitors or other chemotherapeutic agents
EP4093394A1 (en) 2020-01-20 2022-11-30 Astrazeneca AB Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
AU2022463015A1 (en) 2021-10-22 2024-05-09 Tract Pharmaceuticals, Inc. Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues
CN117110469B (zh) * 2023-08-18 2025-12-09 中国检验检疫科学研究院 一种测定防脱发类化妆品中禁用组分的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE69830577T2 (de) 1997-04-15 2006-05-04 Genentech, Inc., South San Francisco Halo-alkoxycarbonylverbindungen
CA2570321C (en) * 2004-07-02 2013-10-08 Genentech, Inc. Inhibitors of iap
KR20120127754A (ko) * 2004-12-20 2012-11-23 제넨테크, 인크. Iap의 피롤리딘 억제제
US8044209B2 (en) 2006-10-12 2011-10-25 Novartis Ag Pyrrolydine derivatives as IAP inhibitors
NZ598890A (en) 2007-04-30 2013-10-25 Genentech Inc Inhibitors of iap
NO2755614T3 (me) * 2012-01-03 2018-03-31
USD690416S1 (en) 2012-12-12 2013-09-24 Pharmajet, Inc. Needle-free syringe

Also Published As

Publication number Publication date
BR112014016637A2 (pt) 2017-06-13
CL2014001770A1 (es) 2015-04-17
UA114417C2 (uk) 2017-06-12
EP3133073B1 (en) 2018-05-02
EP3133073A3 (en) 2017-03-22
HK1203949A1 (en) 2015-11-06
EP2800749B1 (en) 2016-09-21
RU2728789C2 (ru) 2020-07-31
PT2800749T (pt) 2016-10-24
DK2800749T3 (en) 2016-11-07
HUE037760T2 (hu) 2018-09-28
NO2755614T3 (me) 2018-03-31
ME02526B (me) 2017-02-20
KR101553792B1 (ko) 2015-09-16
KR20180051646A (ko) 2018-05-16
MA35895B1 (fr) 2014-12-01
PH12014501534A1 (en) 2014-10-08
US9586991B2 (en) 2017-03-07
RU2016124658A (ru) 2018-12-04
PE20142182A1 (es) 2015-01-16
CA2861637C (en) 2017-07-18
TR201808088T4 (tr) 2018-06-21
LT3133073T (lt) 2018-06-25
CN104159897A (zh) 2014-11-19
JP5747137B2 (ja) 2015-07-08
RU2593259C2 (ru) 2016-08-10
KR20140107670A (ko) 2014-09-04
PH12015501038B1 (en) 2015-09-21
US11963994B2 (en) 2024-04-23
HRP20180976T1 (hr) 2018-08-10
US20160102119A1 (en) 2016-04-14
EP3133073A2 (en) 2017-02-22
MX2014007895A (es) 2015-03-19
US20170136084A1 (en) 2017-05-18
US20220211797A1 (en) 2022-07-07
JP2015504072A (ja) 2015-02-05
AR089623A1 (es) 2014-09-03
BR112014016637B1 (pt) 2022-06-14
US9238675B2 (en) 2016-01-19
ZA201405535B (en) 2017-08-30
RS55327B1 (sr) 2017-03-31
PL3133073T3 (pl) 2018-09-28
US11096982B2 (en) 2021-08-24
BR112014016637A8 (pt) 2017-07-04
RU2016124658A3 (me) 2019-09-09
US20190224269A1 (en) 2019-07-25
MY178390A (en) 2020-10-12
NZ627480A (en) 2016-04-29
KR101917992B1 (ko) 2018-11-13
CY1118371T1 (el) 2017-06-28
CY1120355T1 (el) 2019-07-10
CR20140367A (es) 2015-02-18
US8716236B2 (en) 2014-05-06
HRP20161381T1 (hr) 2016-12-02
EP2800749A1 (en) 2014-11-12
MX336294B (es) 2016-01-14
CO7020915A2 (es) 2014-08-11
ES2672809T3 (es) 2018-06-18
CN107915728A (zh) 2018-04-17
CA2861637A1 (en) 2013-07-11
PT3133073T (pt) 2018-06-18
US20140235551A1 (en) 2014-08-21
DK3133073T3 (en) 2018-06-18
SG11201403784QA (en) 2014-08-28
AU2013202780B2 (en) 2015-04-16
US20130172264A1 (en) 2013-07-04
TW201333001A (zh) 2013-08-16
CN107915728B (zh) 2021-04-30
RS57438B1 (sr) 2018-09-28
KR20150065960A (ko) 2015-06-15
KR101855566B1 (ko) 2018-05-04
EP2800749A4 (en) 2015-08-05
SMT201600357B (it) 2016-11-10
SI2800749T1 (sl) 2016-11-30
AR123542A2 (es) 2022-12-14
TWI503318B (zh) 2015-10-11
WO2013103703A1 (en) 2013-07-11
IL242314A (en) 2016-08-31
SMT201800352T1 (it) 2018-09-13
ES2594856T3 (es) 2016-12-23
HUE031305T2 (hu) 2017-07-28
RU2014130171A (ru) 2016-02-27
PL2800749T3 (pl) 2017-01-31
AU2013202780A1 (en) 2013-07-18
IL233386A0 (en) 2014-08-31
JP2015199738A (ja) 2015-11-12
LT2800749T (lt) 2016-10-25
PH12015501038A1 (en) 2015-09-21
IL233386A (en) 2016-08-31
PH12014501534B1 (en) 2014-10-08
ECSP14011792A (es) 2015-12-31
SI3133073T1 (en) 2018-06-29

Similar Documents

Publication Publication Date Title
NL301268I2 (nl) rozanolixizumab
NO2021049I1 (no) Duvelisib
LT2841428T (lt) Dnr-pk inhibitoriai
EP2763896A4 (en) UNMANUFACTURED AIRCRAFT WITH SEVERAL ROTORS
DK2859055T3 (da) Polymercoatings
EP2880683A4 (en) BVA INTERPOSER
DK2825087T3 (da) Otoscanner
DK2839013T3 (da) Ikke-disruptiv-gen-targetering
EP2809145A4 (en) CHLOROPLAST TRANSIT PEPTIDES
EP2814472A4 (en) DITHIOAMINE REDUCING AGENTS
EP2824794A4 (en) Charging cable
EP2847405A4 (en) DOOR CLOSURE SYSTEM
SMT201600114B (it) Inibitori di beta-secretasi
EP2805877A4 (en) UNDER HOOD
DK2873977T3 (da) Dobbeltdækker-rørdispenser
DE112012006109A5 (de) Okklusionsschienenanordnung
DK2854722T3 (da) Stomipose
EP2941099A4 (en) SWITCHING DEVICE
EP2831482A4 (en) Flange gasket
EP2816694A4 (en) FLAT CABLE WINDING DEVICE
DK2825157T3 (da) Aminosyrelipider
SMT201600357B (it) Inibitori di iap
EP2809729A4 (en) Siloxane polyether copolymers
EP2847201A4 (en) 6-oxo-purin-phosphoribosyl INHIBITORS
EP2862179A4 (en) FUEL CURRENT INSPECTION PROBE